A Case of Pneumocystis jirovecii Pneumonia under Belatacept and Everolimus: Benefit-Risk Balance between Renal Allograft Function and Infection.

MLA

Perrier, Quentin, et al. “A Case of Pneumocystis Jirovecii Pneumonia under Belatacept and Everolimus: Benefit-Risk Balance between Renal Allograft Function and Infection.” Case Reports in Nephrology and Dialysis, vol. 11, no. 1, Jan. 2021, pp. 10–15. EBSCOhost, https://doi.org/10.1159/000510842.

APA

Perrier, Q., Portais, A., Terrec, F., Cerba, Y., Romanet, T., Malvezzi, P., Bedouch, P., Tetaz, R., & Rostaing, L. (2021). A Case of Pneumocystis jirovecii Pneumonia under Belatacept and Everolimus: Benefit-Risk Balance between Renal Allograft Function and Infection. Case Reports in Nephrology and Dialysis, 11(1), 10–15. https://doi.org/10.1159/000510842

Chicago

Perrier, Quentin, Antoine Portais, Florian Terrec, Yann Cerba, Thierry Romanet, Paolo Malvezzi, Pierrick Bedouch, Rachel Tetaz, and Lionel Rostaing. 2021. “A Case of Pneumocystis Jirovecii Pneumonia under Belatacept and Everolimus: Benefit-Risk Balance between Renal Allograft Function and Infection.” Case Reports in Nephrology and Dialysis 11 (1): 10–15. doi:10.1159/000510842.